Ponatinib (AP24534)

Catalog No.S1490

Molecular Weight(MW): 532.56

Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively.

Cited by 83 Publications

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(4):431-443

PubMed: 31543464 ( click the link to review the publication )

Nature, 2016, 534(7609):647-51

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Nature, 2015, 10.1038/nature14329

PubMed: 25970250 ( click the link to review the publication )

Cancer Cell, 2014, 26(2):207-21

PubMed: 25065853 ( click the link to review the publication )

Cancer Cell, 2012, 22(5):656-67

PubMed: 23153538 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 10.1007/s00280-019-04022-x

PubMed: 31901955 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2020, 1864(4):129507

PubMed: 31881245 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2779

PubMed: 31515463 ( click the link to review the publication )

Leukemia, 2019, 33(8):1964-1977

PubMed: 30842608 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Protein Cell, 2019, 10(3):161-177

PubMed: 29667003 ( click the link to review the publication )

Br J Cancer, 2019, 120(6):612-620

PubMed: 30792533 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):1985-1996

PubMed: 31308077 ( click the link to review the publication )

FEBS J, 2019, 286(22):4443-4472

PubMed: 31155838 ( click the link to review the publication )

Front Oncol, 2019, 9:103

PubMed: 30931252 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

Cell Cycle, 2019, 18(18):2307-2322

PubMed: 31349760 ( click the link to review the publication )
Transl Oncol, 2019, 12(9):1221-1228

PubMed: 31276961 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Exp Dermatol, 2019, 10.1111/exd.14010

PubMed: 31338879 ( click the link to review the publication )

Clin Exp Pharmacol Physiol, 2019, 46(2):126-136

PubMed: 30251267 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Sci Adv, 2018, 4(11):eaau0731

PubMed: 30417093 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(8):1932-1943

PubMed: 29440177 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30572654 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1405-1415

PubMed: 29695637 ( click the link to review the publication )

Respir Res, 2018, 19(1):120

PubMed: 29921306 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Oncotarget, 2018, 9(100):37352-37366

PubMed: 30647837 ( click the link to review the publication )

Oncotarget, 2018, 9(65):32496-32506

PubMed: 30197758 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):8

PubMed: 28069043 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-17-0008

PubMed: 28500237 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10-:2130-2143

PubMed: 28751539 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Sci Rep, 2017, 7(1-:5519

PubMed: 28717217 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(6):1455-1467

PubMed: 27733071 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15219

PubMed: 29123157 ( click the link to review the publication )

Gut, 2016, 10.1136/gutjnl-2015-310382

PubMed: 26953272 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1273-1281

PubMed: 27068398 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )
Cancer Sci, 2016, 107(2):140-8

PubMed: 26583567 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Tumour Biol, 2016, 37(2):2365-78

PubMed: 26373734 ( click the link to review the publication )

Oncotarget, 2016, 7(47):78083-78094

PubMed: 27801667 ( click the link to review the publication )

Genes Chromosomes Cancer, 2016, 55(1):60-8

PubMed: 26391436 ( click the link to review the publication )

Oncotarget, 2016, 7(31-:50161-50179

PubMed: 27367030 ( click the link to review the publication )

Sci Transl Med, 2015, 7(298):298ra119

PubMed: 26223302 ( click the link to review the publication )

Nat Commun, 2015, 6:7002

PubMed: 25926053 ( click the link to review the publication )

Leukemia, 2015, 29(5)

PubMed: 25394714 ( click the link to review the publication )

Leukemia, 2015, 29(12):2390-2

PubMed: 26108694 ( click the link to review the publication )

J Med Chem, 2015, 58(23):9228-37

PubMed: 26562217 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

Toxicol Sci, 2015, 143(1):147-55

PubMed: 25304212 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120841

PubMed: 25803811 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(2):133-44

PubMed: 24463606 ( click the link to review the publication )

Sci Transl Med, 2014, 6(261):261ra152

PubMed: 25378644 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Genome Biol, 2014, 15(8):428

PubMed: 25315765 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(9):1316-23

PubMed: 25122427 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2092-103

PubMed: 24436473 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 10.1073/pnas.1321173111

PubMed: 24550512 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(10):2315-27

PubMed: 25053825 ( click the link to review the publication )

Structure, 2014, 22(12):1764-74

PubMed: 25465127 ( click the link to review the publication )
Oncol Rep, 2014, 31(4):1605-12

PubMed: 24481648 ( click the link to review the publication )

Thrombo Res, 2014, 135(1):155-60

PubMed: 25527332 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 446(1):54-60

PubMed: 24565842 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

Harvard University, 2014, Rachel Grace Liao

PubMed: ( click the link to review the publication )

Clin Cancer Res, 2013, 19(6):1422-32

PubMed: 23319824 ( click the link to review the publication )

Cancer Res, 2013, 73(16):5195-205

PubMed: 23786770 ( click the link to review the publication )

Neoplasia, 2013, 15(8):975-88

PubMed: 23908597 ( click the link to review the publication )

Curr Cancer Drug Targets, 2012, 12(5):505-21

PubMed: 22483156 ( click the link to review the publication )

Exp Hematol, 2012, 41(4):335-45.e3

PubMed: 23287417 ( click the link to review the publication )

Mol Genet Metab, 2010, 100(4):309-15

PubMed: 20554235 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcr-Abl Inhibitors

Biological Activity

Description

Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively.

Targets

Abl ^[1] (Cell-free assay)	PDGFRα ^[1] (Cell-free assay)	VEGFR2 ^[1] (Cell-free assay)	FGFR1 ^[1] (Cell-free assay)	c-Src ^[1] (Cell-free assay)	View More
0.37 nM	1.1 nM	1.5 nM	2.2 nM	5.4 nM	View More

In vitro

AP24534 potently inhibits native Abl, Abl^T315I, and other clinically important Abl kinase domain mutants with IC50 of 0.30 nM–2 nM. AP24534 doesn't inhibit Aurora kinase family members, nor does it inhibit insulin receptor or CDK2/cyclin E. AP24534 inhibits proliferation of Ba/F3 cells expressing Bcr-Abl with IC50 of 0.5 nM, as well as Ba/F3 cells expressing a range of Bcr-Abl mutants with IC50 of 0.5 nM–36 nM. The inhibition of proliferation by AP24534 is correlated with induction of apoptosis. ^[1-2] In leukemic cell lines containing activated forms of FLT3, KIT, FGFR1, and PDGFRα receptors, AP24534 potently inhibits receptor phosphorylation and cellular proliferation with IC50 of 0.3 nM to 20 nM. In MV4-11 (FLT3-ITD(+/+)) but not RS4;11 (FLT3-ITD(–/–)) AML cells, AP24534 inhibits FLT3 signaling and induced apoptosis at less than 10 nM. AP24534 inhibits viability of primary leukemic blasts from a FLT3-ITD positive AML patient with IC50 of 4 nM but not those from patients with AML expressing native FLT3. ^[3] In Ba/F3 cells engineered to express activated FGFR1-4, AP24534 potently inhibits FGFR-mediated signaling and viability with IC50 lower than 40 nM. In cell lines representing multiple tumor types (endometrial, bladder, gastric, breast, lung, and colon), and containing FGFRs dysregulated by a variety of mechanisms, AP24534 inhibits FGFR-mediated signaling with IC50 less than 40 nM and inhibits cell growth with IC50 of 7 nM–181 nM. ^[4]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	NHTrNnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPpcnlkUUN3ME2wMlAxODByMECzOVkh\|ryP	MYHTRW5ITVJ?
MV-4-11	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7YTWM2OD1yLkCwNFA6PTZizszN	M2r1UXNCVkeHUh?=
MEG-01	NHW0SWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlKwTWM2OD1yLkCwNFEzQCEQvF2=	NHGyWmRUSU6JRWK=
LAMA-84	M2jtcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDDPXVKSzVyPUCuNFAxOTZ3IN88US=>	M2foUnNCVkeHUh?=
CGTH-W-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjyXWlKSzVyPUCuNFAyPjlizszN	MXzTRW5ITVJ?
KASUMI-1	NEnCdZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfOTWM2OD1yLkCwNlE4KM7:TR?=	Ml;uV2FPT0WU
BE-13	MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTBwMECyOVkh\|ryP	MlnrV2FPT0WU
CTV-1	NFrKO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TWdWlEPTB;MD6wNFUzOSEQvF2=	NWDObmtJW0GQR1XS
NKM-1	MnHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mni0TWM2OD1yLkCwOlU2KM7:TR?=	NI\Cb5FUSU6JRWK=
MONO-MAC-6	NVr4dGppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjnWVBKSzVyPUCuNFA5OzdizszN	MVHTRW5ITVJ?
A204	MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGX6N\|RKSzVyPUCuNFEzOThizszN	MY\TRW5ITVJ?
GDM-1	M1nFXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TCZmlEPTB;MD6wNVg{OyEQvF2=	NEXrZXpUSU6JRWK=
AN3-CA	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvGT2JKSzVyPUCuNFE5PzNizszN	MkXaV2FPT0WU
BL-70	Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTBwMEKxPVkh\|ryP	NXPCdoFDW0GQR1XS
Daudi	Ml\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnuSGtKSzVyPUCuNFI2OzdizszN	NU\JNJZJW0GQR1XS
KU812	NIT6N3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTBwMEK4OFgh\|ryP	NX3lXmlDW0GQR1XS
KG-1	NWPzS4o4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjzRVdsUUN3ME2wMlA{Ojl2IN88US=>	NGnLSW9USU6JRWK=
DOHH-2	NF3C[XNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fKe2lEPTB;MD6wOFgxOyEQvF2=	M2jnWHNCVkeHUh?=
HuO9	MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHTZ3JKSzVyPUCuNFU1PDhizszN	NY\1PFRpW0GQR1XS
EB2	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrvbYw1UUN3ME2wMlA2PTd4IN88US=>	M{[4SHNCVkeHUh?=
G-402	M{Szbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvoVWFKSzVyPUCuNFY{PDFizszN	NVXCcmczW0GQR1XS
SU-DHL-1	NECxfFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fqbWlEPTB;MD6wOlM4QSEQvF2=	M3jhV3NCVkeHUh?=
NCI-H719	MoXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUi3OpJZUUN3ME2wMlA4QDh6IN88US=>	NEHVOIZUSU6JRWK=
MLMA	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTBwMEmwOkDPxE1?	NYmyXnI5W0GQR1XS
KM12	MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\LW5N5UUN3ME2wMlA6PzN5IN88US=>	Mn\YV2FPT0WU
SUP-T1	M{HvTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{H4cWlEPTB;MD6wPVk5OiEQvF2=	NUfBNVRIW0GQR1XS
MZ1-PC	NXGwN2tmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDnSIlVUUN3ME2wMlEyOzN4IN88US=>	MXzTRW5ITVJ?
MFE-296	M2LwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHL2eXZKSzVyPUCuNVE5OzlizszN	M{D4UHNCVkeHUh?=
ALL-PO	M3L6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4riXWlEPTB;MD6xNlQ1OyEQvF2=	M13IUHNCVkeHUh?=
GB-1	NV[3UHJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTBwMUK1NVIh\|ryP	Ml7KV2FPT0WU
SIG-M5	NWjQSVMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHnPYxkUUN3ME2wMlE{OzdizszN	M1y3bnNCVkeHUh?=
P30-OHK	M1TEd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTBwMUW2O\|Ih\|ryP	NGflbFlUSU6JRWK=
NCI-H716	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljZTWM2OD1yLkG2NlY3KM7:TR?=	MlTXV2FPT0WU
MPP-89	M1HrSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MluxTWM2OD1yLkG2PVM{KM7:TR?=	NWnPSHNXW0GQR1XS
SF126	NUC4V4N4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTBwMUewOlMh\|ryP	NWjxbFJHW0GQR1XS
CTB-1	NFPOZ\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGi1OVdKSzVyPUCuNVc{OTZizszN	Mm\tV2FPT0WU
CA46	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXjVHdLUUN3ME2wMlE4PDh7IN88US=>	NYLrU3U{W0GQR1XS
NCI-H520	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUWxV5A2UUN3ME2wMlE4PzN{IN88US=>	MWTTRW5ITVJ?
CAL-85-1	NFf4c\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIT6NIFKSzVyPUCuNVc6OjdizszN	NUfiSo97W0GQR1XS
NCI-H2342	NFSxVWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\SZ3lKSzVyPUCuNVg2PzdizszN	NHj5VHVUSU6JRWK=
697	M3:xV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDLcJNKSzVyPUCuNVg5PzFizszN	NYfyd\|JxW0GQR1XS
NY	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHQenkzUUN3ME2wMlE6Ojh5IN88US=>	M2H0O3NCVkeHUh?=
T98G	NHSwPJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTBwMUmzNVgh\|ryP	Mo\HV2FPT0WU
NCI-H1703	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTVTWM2OD1yLkG5OlE2KM7:TR?=	MXnTRW5ITVJ?
NCI-H2087	NIfxSYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nvO2lEPTB;MD6yNFQ{QSEQvF2=	NYHBdHNQW0GQR1XS
PF-382	M{nzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTBwMkC4O\|Mh\|ryP	M1vNUnNCVkeHUh?=
HCT-116	MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTBwMkGwOlkh\|ryP	NYjaWYtmW0GQR1XS
CAKI-1	M173OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnvTHFZUUN3ME2wMlIyPjZ4IN88US=>	MXnTRW5ITVJ?
CCF-STTG1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\ITWM2OD1yLkKyOFc2KM7:TR?=	MnzNV2FPT0WU
D-392MG	NYT2WVVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX[2[pV7UUN3ME2wMlI{OTd5IN88US=>	NHTROnFUSU6JRWK=
RT-112	NI\LUWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlv2TWM2OD1yLkKzO\|k2KM7:TR?=	NG[xW4FUSU6JRWK=
MES-SA	MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vJeGlEPTB;MD6yOFE5PyEQvF2=	Ml7WV2FPT0WU
LC-2-ad	NYjuT\|FpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGH5TWNKSzVyPUCuNlQzPjVizszN	NFvwUlRUSU6JRWK=
NOS-1	MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\NPGlEPTB;MD6yOFM3PyEQvF2=	M1HaZnNCVkeHUh?=
NALM-6	M1v3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTBwMkW1OFMh\|ryP	MnLXV2FPT0WU
TE-15	Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\5TWM2OD1yLkK2NFkyKM7:TR?=	M4DtXXNCVkeHUh?=
786-0	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrJbYk5UUN3ME2wMlI3OjJ6IN88US=>	MV3TRW5ITVJ?
IST-MES1	NIjhT\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDnSXNKSzVyPUCuNlY5OjlizszN	MW\TRW5ITVJ?
KYSE-180	M3nPb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXUdJpuUUN3ME2wMlI3QDlzIN88US=>	NVPMc45QW0GQR1XS
YT	NGL3NHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHMTWM2OD1yLkK2PVc1KM7:TR?=	MlfRV2FPT0WU
A427	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHCUHFKSzVyPUCuNlczPjRizszN	MmizV2FPT0WU
KYSE-450	M33vfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTBwMkezNlkh\|ryP	NYjl[ZV7W0GQR1XS
HuH-7	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jIWGlEPTB;MD6yO\|c3OyEQvF2=	NWK5bGduW0GQR1XS
CAS-1	NIrUXFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrpTWM2OD1yLkK4N\|A{KM7:TR?=	MmfoV2FPT0WU
KURAMOCHI	NUPTN4N3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PNOWlEPTB;MD6yPFQyQSEQvF2=	NET2SYlUSU6JRWK=
ACHN	NGH5b5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnFNXF3UUN3ME2wMlI6OzJ\|IN88US=>	M3\EenNCVkeHUh?=
HGC-27	MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTBwMkmzOVMh\|ryP	M1nZeHNCVkeHUh?=
A172	MlTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTBwMkm1O\|ch\|ryP	NWnFeYtrW0GQR1XS
SNU-449	NIOzUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\UTVJlUUN3ME2wMlI6QTZ2IN88US=>	M3;ydnNCVkeHUh?=
SW982	NYLOVI9{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfsVWZ2UUN3ME2wMlI6QTd6IN88US=>	Ml3qV2FPT0WU
EFO-21	MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIP2fZlKSzVyPUCuN\|A1OTFizszN	MnnDV2FPT0WU
NCI-H2030	M{TSb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXXWYF{UUN3ME2wMlMyOTZ2IN88US=>	NH3ZcndUSU6JRWK=
HT-144	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDMNJlXUUN3ME2wMlMyOjhizszN	Mo[wV2FPT0WU
MFE-280	MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUSxU\|lmUUN3ME2wMlMyPDV\|IN88US=>	M{HRenNCVkeHUh?=
SK-LU-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnWTWM2OD1yLkOxOFY3KM7:TR?=	MoW4V2FPT0WU
NCI-H2052	NEPkWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTBwM{G0PFQh\|ryP	MUnTRW5ITVJ?
SK-HEP-1	NHnMPZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFz0PIpKSzVyPUCuN\|M{PjhizszN	NEDy[pZUSU6JRWK=
QIMR-WIL	NFHqVJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjFTWM2OD1yLkOzOFI1KM7:TR?=	MVjTRW5ITVJ?
A2780	M1nUSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnVZVRKSzVyPUCuN\|Q{ODRizszN	Ml\JV2FPT0WU
ACN	NVjqcZloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjDTWM2OD1yLkO0PFc{KM7:TR?=	NE\KfJZUSU6JRWK=
BxPC-3	M4G3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;YTWM2OD1yLkO0PVg6KM7:TR?=	NITzTZJUSU6JRWK=
BCPAP	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTaTWM2OD1yLkO2NFAyKM7:TR?=	NIfJZmxUSU6JRWK=
HOP-62	M4TzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LWPWlEPTB;MD6zOlExPiEQvF2=	MXrTRW5ITVJ?
SW1710	M{DDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTBwM{[0OVUh\|ryP	NHXldFVUSU6JRWK=
OPM-2	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTBwM{[0O\|Mh\|ryP	MnroV2FPT0WU
DBTRG-05MG	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYS1[FNoUUN3ME2wMlM5ODV2IN88US=>	NFrrPZNUSU6JRWK=
SK-MEL-24	MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPPTWM2OD1yLkO5O\|kyKM7:TR?=	NHjuXYdUSU6JRWK=
8305C	NWnaZ5JJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTBwM{m3PVMh\|ryP	NUW2[XE{W0GQR1XS
OVCAR-4	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3G1TGlEPTB;MD60NVU5PiEQvF2=	NV3tOoFHW0GQR1XS
HLE	NUi1OoZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33Tc2lEPTB;MD60NVg3KM7:TR?=	MXXTRW5ITVJ?
NCI-H747	NV3KU\|Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3S4RmlEPTB;MD60NlE{PyEQvF2=	MWXTRW5ITVJ?
SW780	M2nQ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDJV45VUUN3ME2wMlQzOzR4IN88US=>	NF\FVWhUSU6JRWK=
KYSE-150	NFLDRVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PUeGlEPTB;MD60NlQyPSEQvF2=	NF;ES5NUSU6JRWK=
H4	M4\YTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwNEK0OVEh\|ryP	NF3J[lNUSU6JRWK=
SW1088	MkDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfCZWdjUUN3ME2wMlQ1OzlizszN	M3XZdnNCVkeHUh?=
SF268	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTBwNES4OkDPxE1?	M3TxTHNCVkeHUh?=
RT4	NUHjZoQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTBwNEWxNVEh\|ryP	NFfqUG5USU6JRWK=
NCI-H522	M{L5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvmbJBKSzVyPUCuOFUzPyEQvF2=	M1u2b3NCVkeHUh?=
LCLC-97TM1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M16zbWlEPTB;MD60OlE6PSEQvF2=	MlXEV2FPT0WU
CAL-39	MlPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\MbWlEPTB;MD60OlUyQSEQvF2=	MYjTRW5ITVJ?
CAL-120	NYDXPJdwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XoO2lEPTB;MD60O\|Y1OyEQvF2=	MmrjV2FPT0WU
ESS-1	Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDu[YUzUUN3ME2wMlQ4QDJzIN88US=>	NGjMVFBUSU6JRWK=
KARPAS-45	M2jQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7KTWM2OD1yLkS4PVM{KM7:TR?=	MXHTRW5ITVJ?
DU-4475	NFnQWWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTBwNEm1NVEh\|ryP	MUjTRW5ITVJ?
VMRC-RCZ	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlr2TWM2OD1yLkS5PVA1KM7:TR?=	NVPJSXpJW0GQR1XS
HOS	NUWzV\|hMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzJTWM2OD1yLkWwN\|Y2KM7:TR?=	M{CxcHNCVkeHUh?=
MOLT-16	M2LVXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfNTWM2OD1yLkWxPFA5KM7:TR?=	NGjpXYJUSU6JRWK=
RPMI-6666	NGmyWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnxTWM2OD1yLkWyNVM2KM7:TR?=	Mkn1V2FPT0WU
K052	M2rTZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\QTWM2OD1yLkWyNVQh\|ryP	M3TndXNCVkeHUh?=
EHEB	NEH3NIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\yN4hKSzVyPUCuOVIyQDJizszN	MV7TRW5ITVJ?
MFH-ino	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPqTYZKSzVyPUCuOVI{PTFizszN	MY\TRW5ITVJ?
A4-Fuk	MnHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTBwNUK1Nlgh\|ryP	M{i3cHNCVkeHUh?=
SW1417	M{OwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;4TWM2OD1yLkWyO\|gyKM7:TR?=	NUP4UmpzW0GQR1XS
DoTc2-4510	Mlf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTBwNUS5OVgh\|ryP	MoDWV2FPT0WU
TE-12	NXqyeXM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV:0WJJLUUN3ME2wMlU2PzN3IN88US=>	NYPUXIpQW0GQR1XS
8-MG-BA	M{O1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTBwNU[wOVYh\|ryP	MX\TRW5ITVJ?
ECC12	NFWzdZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTBwNU[1OVgh\|ryP	NVroTW8zW0GQR1XS
CHL-1	NY\6dVlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHvPXVWUUN3ME2wMlU4PDZ\|IN88US=>	Mm[3V2FPT0WU
LCLC-103H	M3zUV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jHdmlEPTB;MD61PFM1PCEQvF2=	NEnOcFJUSU6JRWK=
OS-RC-2	M1[3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrKWnlyUUN3ME2wMlU5Ozd7IN88US=>	Mor1V2FPT0WU
RO82-W-1	NGfrOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHpTWM2OD1yLkW5OlE2KM7:TR?=	MmrUV2FPT0WU
A3-KAW	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwNkG0Olch\|ryP	NFnkSJpUSU6JRWK=
NCCIT	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTBwNkG3NVUh\|ryP	NFPHXHdUSU6JRWK=
IST-SL2	NFLqSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fYWmlEPTB;MD62NlUzOiEQvF2=	MYTTRW5ITVJ?
GI-ME-N	NFi3WoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXVN2w1UUN3ME2wMlY{ODZ7IN88US=>	MUnTRW5ITVJ?
ES6	MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLHTWM2OD1yLk[zNlk2KM7:TR?=	NWjU[Y9TW0GQR1XS
BL-41	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLjcnJKSzVyPUCuOlM{PTJizszN	M1u0[HNCVkeHUh?=
Ca-Ski	MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3WTWM2OD1yLk[0PFEh\|ryP	NWm1ZoI5W0GQR1XS
HOP-92	NYm1fWE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTBwNkW2O\|Ih\|ryP	MmHwV2FPT0WU
SK-LMS-1	MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nzfGlEPTB;MD62OlQ4KM7:TR?=	MWPTRW5ITVJ?
EW-13	NHTaVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHj4UlZKSzVyPUCuOlY4PzlizszN	NVjCTIlxW0GQR1XS
647-V	MkHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vJZ2lEPTB;MD62PFE1QCEQvF2=	NVjXWIZDW0GQR1XS
JiyoyeP-2003	MkfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIf4NmdKSzVyPUCuOlk4OzhizszN	NWnoXpU6W0GQR1XS
WSU-NHL	NX3QUFR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnn1TWM2OD1yLkewPFg4KM7:TR?=	NInqbJNUSU6JRWK=
U-698-M	NXr1Sod5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVG4WYdNUUN3ME2wMlcyODZ\|IN88US=>	MV;TRW5ITVJ?
HC-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHm4Zm1KSzVyPUCuO\|I1ODVizszN	MnjNV2FPT0WU
8505C	NXm2SHlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\WTWM2OD1yLkeyO\|QyKM7:TR?=	NWfyZWJUW0GQR1XS
HUTU-80	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwN{OzOFkh\|ryP	M3;FVHNCVkeHUh?=
LB1047-RCC	Mn31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrKTWM2OD1yLkezOVM5KM7:TR?=	MVfTRW5ITVJ?
GAMG	M3jVfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PRd2lEPTB;MD63N\|Y2OyEQvF2=	MoXTV2FPT0WU
CAL-12T	NXm2RmJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo[5TWM2OD1yLkezPFc4KM7:TR?=	MXTTRW5ITVJ?
NCI-SNU-1	NWTYNYZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPRTWM2OD1yLke3Nlc5KM7:TR?=	MUjTRW5ITVJ?
HTC-C3	NGK1c5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjyW2NqUUN3ME2wMlc4PDVzIN88US=>	NIjnelJUSU6JRWK=
HPAF-II	NWL2XJhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF2zeWZKSzVyPUCuO\|c2ODFizszN	MXvTRW5ITVJ?
KGN	NW\wXGtxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTDR4FJUUN3ME2wMlc5ODhzIN88US=>	M4jweHNCVkeHUh?=
EFO-27	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTBwN{i3N\|Mh\|ryP	MXnTRW5ITVJ?
MEL-HO	NWT0fI1tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3G3b2lEPTB;MD63PVQ1QSEQvF2=	NV\4[I5DW0GQR1XS
KYSE-270	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3WdmFTUUN3ME2wMlgxPTJ7IN88US=>	MWDTRW5ITVJ?
NCI-H1755	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEG2TWRKSzVyPUCuPFA4OTRizszN	M1:0SnNCVkeHUh?=
MFM-223	NGnhWVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofwTWM2OD1yLkixOFA4KM7:TR?=	NXzNcINzW0GQR1XS
G-361	NV[5UotZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XwTGlEPTB;MD64NVg6PyEQvF2=	MnLuV2FPT0WU
ETK-1	NFnCeWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3TDUGlEPTB;MD64NlQ1OSEQvF2=	MlnOV2FPT0WU
LU-99A	MnvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwOES3NFEh\|ryP	MlfNV2FPT0WU
IST-MEL1	M1LsZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Lq[mlEPTB;MD64OVc{OiEQvF2=	NVTHSWd[W0GQR1XS
L-540	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrQTWM2OD1yLki1PFAyKM7:TR?=	M3jCNXNCVkeHUh?=
U-2-OS	NIric4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTBwOEW4OFYh\|ryP	M3fyZ3NCVkeHUh?=
HT-1376	MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjVd5FKSzVyPUCuPFYxPTFizszN	M1jyVHNCVkeHUh?=
COLO-680N	Moj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;QWlRKSzVyPUCuPFc6OzNizszN	MXfTRW5ITVJ?
NCI-H1581	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIWyboNKSzVyPUCuPFkzQTdizszN	NH7nOY9USU6JRWK=
HuCCT1	NX7NXoFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPLT5JyUUN3ME2wMlg6PTR6IN88US=>	NITEflZUSU6JRWK=
BB30-HNC	MnHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrG[JRKSzVyPUCuPVI1PjlizszN	MXrTRW5ITVJ?
NCI-H2347	NEP5dnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfDOmdKSzVyPUCuPVMzQTJizszN	M{jHOXNCVkeHUh?=
G-401	MmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTBwOUO2PVUh\|ryP	M4H2cHNCVkeHUh?=
NCI-H358	NWP4PXo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTBwOUWwNVQh\|ryP	Mn;OV2FPT0WU
HCC1395	MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTBwOUW0OlEh\|ryP	M2\uOHNCVkeHUh?=
J82	Ml62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwOUW1OFMh\|ryP	MlPVV2FPT0WU
KE-37	NUXnT2d4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HuZmlEPTB;MD65OlM5PyEQvF2=	M1[wNHNCVkeHUh?=
NOMO-1	M3LQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTBwOU[1OlQh\|ryP	NX;NdnU1W0GQR1XS
ML-2	NF\nOHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfsTWM2OD1yLkm5O\|Uh\|ryP	NEK3VGtUSU6JRWK=
SW872	MlvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TNdmlEPTB;MD65PVc4PSEQvF2=	MliyV2FPT0WU
KYSE-520	MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PofGlEPTB;MT6wNFQ6PCEQvF2=	MVvTRW5ITVJ?
HL-60	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M330XmlEPTB;MT6wNFk4KM7:TR?=	NFLkO5FUSU6JRWK=
HDLM-2	NHLGNFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2e3RWlEPTB;MT6wNVI2OiEQvF2=	NGjLfYxUSU6JRWK=
MIA-PaCa-2	NULY[3lWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH2yW3VKSzVyPUGuNFE{PzVizszN	NXfoOIFYW0GQR1XS
TCCSUP	NVzododOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFf6W2lKSzVyPUGuNFE4OzJizszN	MXfTRW5ITVJ?
SH-4	NFnYfnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvZTWM2OD1zLkCyNlQ1KM7:TR?=	NWTiOVlxW0GQR1XS
MG-63	M3TDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnjZotKSzVyPUGuNFI3OTZizszN	MnLOV2FPT0WU
NB6	M{TkO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTFwMEOxNFkh\|ryP	MlTuV2FPT0WU
CAL-54	M3nL[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2S4TWlEPTB;MT6wN\|k2QSEQvF2=	NGDCOVlUSU6JRWK=
DU-145	MojlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkf0TWM2OD1zLkC4NFc{KM7:TR?=	M3frTXNCVkeHUh?=
HCE-4	M4Wwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\WR2RGUUN3ME2xMlA6Ojh4IN88US=>	NI\PR\|hUSU6JRWK=
U-266	NEPDfFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2f2[2lEPTB;MT6wPVY{OyEQvF2=	Mn[1V2FPT0WU
HT-1197	MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoriTWM2OD1zLkGxOFM5KM7:TR?=	NX;OXmh7W0GQR1XS
EW-1	NIO0OGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojCTWM2OD1zLkG0NVI5KM7:TR?=	M1u4cnNCVkeHUh?=
MHH-NB-11	NUjiZ2ltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDJTWM2OD1zLkG1N\|Y5KM7:TR?=	NEHuVXhUSU6JRWK=
NCI-H2405	NEf0cHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LFUmlEPTB;MT6xOlE3KM7:TR?=	M1\mZXNCVkeHUh?=
COLO-668	NHfLbI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTFwMU[0PUDPxE1?	MXHTRW5ITVJ?
IMR-5	NGL6XGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLGbZJXUUN3ME2xMlE3QTN4IN88US=>	M1\ne3NCVkeHUh?=
ARH-77	MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4C2NGlEPTB;MT6yNlkzPCEQvF2=	MXrTRW5ITVJ?
BHT-101	NXT0RZdJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnmTWM2OD1zLkKzOFkh\|ryP	NYWzNYhTW0GQR1XS
SCC-25	MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmD0TWM2OD1zLkKzOVM3KM7:TR?=	NWrNblBKW0GQR1XS
NTERA-S-cl-D1	NG\zfVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvYd21KSzVyPUGuNlQ{PDZizszN	M2rTdnNCVkeHUh?=
MKN28	NEHwOJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTYUnZKSzVyPUGuNlU3OzZizszN	MnvBV2FPT0WU
KS-1	M3jBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\mWphVUUN3ME2xMlI5OjZ7IN88US=>	NFnY[2pUSU6JRWK=
NCI-H1734	NIO4[\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mni5TWM2OD1zLkK4PVE{KM7:TR?=	NGnLZo9USU6JRWK=
ES7	NF;QbHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{j4O2lEPTB;MT6yPVU1OiEQvF2=	MUPTRW5ITVJ?
NCI-H838	MnfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTFwM{C2NVUh\|ryP	NIrHUY5USU6JRWK=
HEC-1	M4C0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTFwM{O3OVUh\|ryP	NF;OO41USU6JRWK=
ME-180	M4ey[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\URY1KSzVyPUGuN\|c6QTNizszN	M4Kx[XNCVkeHUh?=
MMAC-SF	M12wTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTFwM{m1PVUh\|ryP	MUfTRW5ITVJ?
IA-LM	M3\1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjnTWM2OD1zLkSwPVE1KM7:TR?=	MWHTRW5ITVJ?
MN-60	M2e4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDvcpBKSzVyPUGuOFMyOTRizszN	MWDTRW5ITVJ?
SIMA	NIiyS45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfUPZNXUUN3ME2xMlQ5Pjh5IN88US=>	Ml\NV2FPT0WU
NCI-H1770	M4ixU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETkWIxKSzVyPUGuOVIxPTRizszN	M{HyNXNCVkeHUh?=
ONS-76	M3TZTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTYdZhbUUN3ME2xMlUzOzFzIN88US=>	M2P3fXNCVkeHUh?=
LB771-HNC	NWLDe2NbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTFwNUO5NFYh\|ryP	NWL1ZXFRW0GQR1XS
SW48	MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvqTWM2OD1zLkW0NlQ{KM7:TR?=	Mli5V2FPT0WU
KYSE-140	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;uT\|IzUUN3ME2xMlU2PzRzIN88US=>	NYC4RmpyW0GQR1XS
SW626	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojsTWM2OD1zLkW4NVYh\|ryP	NHTMVYxUSU6JRWK=
MC-CAR	NWLJO3hGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTFwNUi2OlMh\|ryP	M33m[nNCVkeHUh?=
D-336MG	NEmxcIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrzenFKSzVyPUGuOlI6PCEQvF2=	MV3TRW5ITVJ?
SK-MEL-3	M1;JdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTFwNkO5NFIh\|ryP	NEfhcIFUSU6JRWK=
MHH-PREB-1	NWjYZZBJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlz1TWM2OD1zLk[0OFc{KM7:TR?=	MXTTRW5ITVJ?
Calu-1	NXeyd3l3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjkTWM2OD1zLk[1N\|g3KM7:TR?=	M2riN3NCVkeHUh?=
HCC1806	NHzo[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYm1bVZOUUN3ME2xMlY3PjFzIN88US=>	NInjWJpUSU6JRWK=
A101D	NXHJcFVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vLOGlEPTB;MT62Olc5OSEQvF2=	M4fUS3NCVkeHUh?=
A704	NWTQTVk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXiTWM2OD1zLk[4N\|EyKM7:TR?=	NEK3XpBUSU6JRWK=
LB831-BLC	MmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3JTWM2OD1zLk[5PFU1KM7:TR?=	NEfXWVBUSU6JRWK=
RL95-2	M1rmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;yVFZKSzVyPUGuO\|E1PjNizszN	NX20UG5TW0GQR1XS
RPMI-2650	NX76OFZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHe4T4FKSzVyPUGuO\|I4OTlizszN	NHfXdnpUSU6JRWK=
NH-12	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTFwN{O0Nlch\|ryP	MUfTRW5ITVJ?
AGS	Mnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXSxWWs3UUN3ME2xMlc3OzV6IN88US=>	Mle5V2FPT0WU
NEC8	NXz5W4c2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvVTpBKSzVyPUGuO\|g6QTVizszN	MXrTRW5ITVJ?
NCI-H2009	NVPycI03T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVuwT2hQUUN3ME2xMlc6PzJzIN88US=>	MYDTRW5ITVJ?
A498	NGTKWnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2i5O2lEPTB;MT64NVI5OiEQvF2=	NXy5c2dyW0GQR1XS
NCI-H810	NH7LUY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\FNGh2UUN3ME2xMlgyPjB4IN88US=>	M{S4THNCVkeHUh?=
SK-NEP-1	M4jobWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTFwOEO3Olch\|ryP	MkXHV2FPT0WU
D-542MG	M3PiPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvIfmR7UUN3ME2xMlg2QDVzIN88US=>	MnfQV2FPT0WU
KNS-42	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnG4TWM2OD1zLki2NlY3KM7:TR?=	NUKx[VlFW0GQR1XS
NCI-H2452	MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoG2TWM2OD1zLki5NFc1KM7:TR?=	MoHWV2FPT0WU
SK-MEL-2	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHOfYZKSzVyPUGuPVAzPzFizszN	NITpWIZUSU6JRWK=
OVCAR-5	NFzub3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\Ed\|VkUUN3ME2xMlkxPjd3IN88US=>	NFyxOoNUSU6JRWK=
SNG-M	NFXSOpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zuNWlEPTB;MT65OVg2QCEQvF2=	NFGzOmFUSU6JRWK=
A673	NX7KWGtCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPwRYxIUUN3ME2xMlk4PTF4IN88US=>	MnvRV2FPT0WU
L-428	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\LcZVKSzVyPUGuPVkyPzlizszN	MlX3V2FPT0WU
KM-H2	M{nCb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLHbIhiUUN3ME2yMlAyODlizszN	NVfOT4VQW0GQR1XS
MC-IXC	MnvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3MNXhyUUN3ME2yMlAzOjd\|IN88US=>	MV7TRW5ITVJ?
COLO-678	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvZTWM2OD1{LkC0NlA4KM7:TR?=	MWnTRW5ITVJ?
MEL-JUSO	MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTJwMEe4OVEh\|ryP	MnXBV2FPT0WU
HCC38	NVzBcWs2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjsSng3UUN3ME2yMlA5PDN\|IN88US=>	M{LpSnNCVkeHUh?=
UACC-62	MmOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH:wPGRKSzVyPUKuNFg5PTVizszN	NYHz[YRzW0GQR1XS
OAW-42	M{ewZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHPTZFGUUN3ME2yMlA6PzFzIN88US=>	Mn;KV2FPT0WU
LB996-RCC	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2K5eWlEPTB;Mj6xN\|gyPyEQvF2=	MUfTRW5ITVJ?
COR-L105	NEPLOWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXIbZdIUUN3ME2yMlE3Ozd\|IN88US=>	NFXyT\|dUSU6JRWK=
RCC10RGB	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnLcZRRUUN3ME2yMlE5PTd4IN88US=>	NX;OSJhuW0GQR1XS
A431	NVW3bJY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTJwMUmwNVkh\|ryP	M4DyR3NCVkeHUh?=
NCI-H292	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;3R2RKSzVyPUKuNlM6PTFizszN	M1r0[3NCVkeHUh?=
SK-UT-1	NXfWSotxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXVTWM2OD1{LkOzNVg1KM7:TR?=	MVPTRW5ITVJ?
PANC-08-13	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPGWJhKSzVyPUKuN\|MzOzVizszN	MUnTRW5ITVJ?
ST486	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrVTWM2OD1{LkSxNFQ5KM7:TR?=	M4rwOnNCVkeHUh?=
SJSA-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3i2fmlEPTB;Mj60NVI4OSEQvF2=	Mm\FV2FPT0WU
RKO	MoDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7hTWM2OD1{LkSyNFI6KM7:TR?=	NHjwRnlUSU6JRWK=
NCI-H1793	NEfRPHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTJwNESwNlkh\|ryP	M1\nOHNCVkeHUh?=
639-V	NIXPOpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrjU3dKSzVyPUKuOFU{QDJizszN	NGn6TZlUSU6JRWK=
ES3	M320Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PlOmlEPTB;Mj60PVc{PyEQvF2=	MlTtV2FPT0WU
NCI-H1792	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTJwNU[4NlYh\|ryP	NFzN[2ZUSU6JRWK=
NCI-H1651	MkXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrlTWM2OD1{LkW4NlEh\|ryP	MV\TRW5ITVJ?
SN12C	NIj6VWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTJwNUi0PFch\|ryP	NGK3UnFUSU6JRWK=
COLO-679	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUOzVmZQUUN3ME2yMlU5PjB3IN88US=>	NUi2OnIyW0GQR1XS
U-118-MG	NX\wSFNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTJwNUi4O\|Ih\|ryP	MnLlV2FPT0WU
Ramos-2G6-4C10	M1vQXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojlTWM2OD1{Lk[0PFA4KM7:TR?=	MUPTRW5ITVJ?
HCT-15	NHjpPVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2m2XmlEPTB;Mj62PFc6OiEQvF2=	NIL6epBUSU6JRWK=
MDA-MB-157	M4\ETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETuVlJKSzVyPUKuO\|A4PDdizszN	NFXDXpBUSU6JRWK=
K5	NXvW[Jg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4GwNGlEPTB;Mj63NVg1PSEQvF2=	NYnRPZdtW0GQR1XS
MKN45	NIT3NY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI[3cYFKSzVyPUKuO\|M{PjZizszN	M2rBN3NCVkeHUh?=
DMS-273	Mm\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPZTWM2OD1{Lke1OlMzKM7:TR?=	MnnSV2FPT0WU
C8166	M3;oSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjXb5VqUUN3ME2yMlc5PTF\|IN88US=>	MWjTRW5ITVJ?
Calu-3	M2jYOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPPTWM2OD1{Lke4PVY6KM7:TR?=	NIfufHdUSU6JRWK=
SNB75	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LxN2lEPTB;Mj64PFU{PSEQvF2=	MYnTRW5ITVJ?
BFTC-905	MkLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkf1TWM2OD1{LkmwNVkyKM7:TR?=	M1nKUnNCVkeHUh?=
C-4-II	Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrVTWM2OD1{LkmxN\|U{KM7:TR?=	NWPFfHBzW0GQR1XS
MS-1	Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml2wTWM2OD1{Lkm2O\|Y6KM7:TR?=	MUPTRW5ITVJ?
A375	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnSNYRZUUN3ME2zMlA5OTh2IN88US=>	MoHEV2FPT0WU
KYSE-70	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXDTWM2OD1\|LkC4PFgzKM7:TR?=	M1iwU3NCVkeHUh?=
KYSE-510	NG\QZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXIV2dKSzVyPUOuNVA6QTVizszN	NU\KWZhrW0GQR1XS
LN-405	M1HUb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnzdm5oUUN3ME2zMlE{PTF6IN88US=>	NF;Ye2hUSU6JRWK=
BOKU	MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HaV2lEPTB;Mz6xOFI2PiEQvF2=	MlHQV2FPT0WU
TE-10	M1fHOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3Zbo9KSzVyPUOuNVc{PjJizszN	NWHhUVZmW0GQR1XS
MKN1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnwOJVMUUN3ME2zMlE5PDh\|IN88US=>	NVTjfFUyW0GQR1XS
M059J	M13U[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHKUFNDUUN3ME2zMlIxOTd\|IN88US=>	NFLGO5VUSU6JRWK=
GOTO	NHrSc5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYP5TFI6UUN3ME2zMlIzODN7IN88US=>	MUHTRW5ITVJ?
DK-MG	NH30eGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTNwMkW5O\|Yh\|ryP	NVy3NJZ5W0GQR1XS
NCI-H727	NVrUbId[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnGTXJKSzVyPUOuNlY2QCEQvF2=	NWPabXl5W0GQR1XS
NB12	M3vKR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTNwM{OyNlQh\|ryP	NYjBTYF4W0GQR1XS
DOK	NWDoZVduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTNwM{[xPFYh\|ryP	NH;0dndUSU6JRWK=
KYSE-410	MlnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\XSXRKSzVyPUOuN\|YzQDdizszN	M1X4S3NCVkeHUh?=
AM-38	Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTNwM{iwOVEh\|ryP	NITZN2FUSU6JRWK=
GR-ST	MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXRZZRbUUN3ME2zMlQ2PzN{IN88US=>	NYTNdo1HW0GQR1XS
D-247MG	NYOzcYVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPURWRFUUN3ME2zMlQ5OjZ\|IN88US=>	M4ewUXNCVkeHUh?=
TE-8	NGHnUGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LCWGlEPTB;Mz60PVM{OyEQvF2=	NFT2O2xUSU6JRWK=
LS-411N	MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTNwNEm2PVIh\|ryP	MofMV2FPT0WU
SK-MES-1	NXXXOGNCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnzTWM2OD1\|LkW2OFM{KM7:TR?=	NGXNdIFUSU6JRWK=
SF295	Mlf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;hTWM2OD1\|Lk[xOVUzKM7:TR?=	NIfwcnhUSU6JRWK=
SK-MEL-30	NHfzWlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTNwNkW5NlEh\|ryP	MnTBV2FPT0WU
LB2241-RCC	M1XzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnL2TWM2OD1\|Lk[2NlYh\|ryP	MnmyV2FPT0WU
PC-14	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HaOWlEPTB;Mz62OlQ{PyEQvF2=	MXjTRW5ITVJ?
EW-7	NVHmUXJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnqeHlMUUN3ME2zMlY4Pjl\|IN88US=>	NFPjUndUSU6JRWK=
NMC-G1	NHXpSpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTNwN{G4N\|ch\|ryP	MXzTRW5ITVJ?
TE-441-T	NW\nW4Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnmUoJJUUN3ME2zMlc{ODJ6IN88US=>	NFOy[5VUSU6JRWK=
NCI-H1618	MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;LTWM2OD1\|LkixPFc2KM7:TR?=	MlTqV2FPT0WU
PANC-03-27	NFnmb3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mkn6TWM2OD1\|LkixPVE3KM7:TR?=	MX7TRW5ITVJ?
NCI-H2228	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTNwOEOxNlYh\|ryP	MnzEV2FPT0WU
CAPAN-1	NGXiUnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYC0dWw6UUN3ME2zMlg4ODB7IN88US=>	NYTIOWNCW0GQR1XS
KLE	M1fPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\leGlEPTB;Mz65NFY4KM7:TR?=	NX2xVYQxW0GQR1XS
Becker	NFOxeHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfQSHlUUUN3ME2zMlkzQDR7IN88US=>	M2H2UXNCVkeHUh?=
SK-PN-DW	MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\VTWM2OD12LkC3PVc1KM7:TR?=	M1HtNXNCVkeHUh?=
Hs-578-T	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2f3TWlEPTB;ND6wPFMxPiEQvF2=	MUTTRW5ITVJ?
RS4-11	NIr1dIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHe4dWhKSzVyPUSuNVEzPTVizszN	MoSxV2FPT0WU
D-502MG	NEDLSnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnSyTWM2OD12LkG2PVk4KM7:TR?=	NGnwW5hUSU6JRWK=
GI-1	NX7pSZF7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLQTWM2OD12LkK4Nlk6KM7:TR?=	NF3INm5USU6JRWK=
NCI-H209	MoPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXVTnVKSzVyPUSuN\|M4QCEQvF2=	MkXKV2FPT0WU
SK-OV-3	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLP[pBKSzVyPUSuOFgyPDlizszN	M17KVHNCVkeHUh?=
LOUCY	M{XlZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTRwNEi0N\|Ih\|ryP	M4DE[nNCVkeHUh?=
NCI-H69	NWTl[FBnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDRNpd4UUN3ME20MlUyPzl\|IN88US=>	Ml\4V2FPT0WU
SCC-9	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWG5UnNiUUN3ME20MlU{OTd{IN88US=>	MlfvV2FPT0WU
NCI-H526	NFXXXYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTtNpROUUN3ME20MlU6Ojl\|IN88US=>	M1rWSXNCVkeHUh?=
NCI-H2170	NI\Jc3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPJTWM2OD12Lk[2O\|cyKM7:TR?=	MmG0V2FPT0WU
SR	M1nZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mln1TWM2OD12LkewNFQ5KM7:TR?=	NUX3XJRMW0GQR1XS
CMK	NUnFO\|c3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTRwN{KxNFEh\|ryP	MnK2V2FPT0WU
COLO-829	M{LtfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvnTWM2OD12Lke3NFQ{KM7:TR?=	MlTPV2FPT0WU
HuO-3N1	NELUeYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\HTWM2OD12LkizNlgyKM7:TR?=	NFfwR3NUSU6JRWK=
5637	NXPoT4dUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nW[WlEPTB;ND65NFQ5PyEQvF2=	MmTVV2FPT0WU
A253	Mo\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PM[2lEPTB;ND65O\|cxQCEQvF2=	M3PCd3NCVkeHUh?=
NB10	NIS3VGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PsR2lEPTB;NT6wO\|Q6PyEQvF2=	MknzV2FPT0WU
SF539	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVviVZpSUUN3ME21MlA6QTV7IN88US=>	MYfTRW5ITVJ?
HAL-01	MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHrTWM2OD13LkG0OlQ2KM7:TR?=	MYXTRW5ITVJ?
MHH-ES-1	NUjSVnVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3W1dWlEPTB;NT6xOlkzPSEQvF2=	NFjjcJRUSU6JRWK=
DEL	NV:3cWV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrye2R4UUN3ME21MlI4PTh{IN88US=>	MmDYV2FPT0WU
NCI-H1299	M{DLbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPaTWFKSzVyPUWuN\|UxODdizszN	MYXTRW5ITVJ?
ChaGo-K-1	NFXOUmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLpN2ZKSzVyPUWuN\|UyODdizszN	NFnOd\|NUSU6JRWK=
HMV-II	M{Xyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk[3TWM2OD13LkO5OFMh\|ryP	MUDTRW5ITVJ?
NB69	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LmRmlEPTB;NT6zPVY{OSEQvF2=	Mo\TV2FPT0WU
NCI-H1882	MorMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTVwNEOzOlQh\|ryP	MYXTRW5ITVJ?
SNU-475	NWfoWVZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPzSFFKSzVyPUWuOFcyPzFizszN	NXfNSIdTW0GQR1XS
RXF393	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHqxRXJKSzVyPUWuOFg1QTRizszN	NXntfI1FW0GQR1XS
CAL-51	NVPmZ2xxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV:xcGpmUUN3ME21MlYzQDV\|IN88US=>	MmTJV2FPT0WU
SW1573	M1jENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfxTWM2OD13Lk[zOVM1KM7:TR?=	MmLHV2FPT0WU
GCT	NGnic\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvkOXVKSzVyPUWuO\|U6OjlizszN	NXfrOIpIW0GQR1XS
COR-L88	NVfXcld[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTRTWM2OD13Lke2PFQ3KM7:TR?=	M{[xdnNCVkeHUh?=
MDA-MB-134-VI	MoTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojVTWM2OD13Lki3OVM3KM7:TR?=	M3vSTnNCVkeHUh?=
NB5	M1zOZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELzSIpKSzVyPUWuPVI1PCEQvF2=	MofhV2FPT0WU
GMS-10	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{j6UmlEPTB;NT65Olg3OSEQvF2=	M4nmcXNCVkeHUh?=
CHP-212	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPWTWM2OD14LkS4NlY4KM7:TR?=	M1foNnNCVkeHUh?=
TE-11	MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHUR\|N7UUN3ME22MlU2OTh{IN88US=>	MnvEV2FPT0WU
SW962	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVf4b5ZKUUN3ME22MlY2Pzd2IN88US=>	MX\TRW5ITVJ?
MZ2-MEL	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTZwOEKwNVEh\|ryP	M4PMc3NCVkeHUh?=
C-33-A	NEH6[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXG2b21qUUN3ME22MlkyPjh6IN88US=>	MYTTRW5ITVJ?
IGR-1	M2HFNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zzTWlEPTB;Nj65O\|gzPiEQvF2=	NEDUU5VUSU6JRWK=
MOLT-4	NXrYRpdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInCW4pKSzVyPUeuNVU1ODZizszN	MXvTRW5ITVJ?
NCI-H1650	NHLueZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofsTWM2OD15LkK3NFQ3KM7:TR?=	NHTnbVBUSU6JRWK=
AsPC-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTCe\|RyUUN3ME23MlI5PjB3IN88US=>	M{m0ZnNCVkeHUh?=
SNU-C2B	M1jvR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTnR49KSzVyPUeuNlk2PzFizszN	NH\adHZUSU6JRWK=
MKN7	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{ftVmlEPTB;Nz6zO\|I{PSEQvF2=	Ml60V2FPT0WU
SW620	NVnMTlFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXZTWM2OD15LkO4NlA2KM7:TR?=	NF;aU5FUSU6JRWK=
SK-MEL-28	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2L2eGlEPTB;Nz60NFc6QCEQvF2=	MmLKV2FPT0WU
TE-6	M2fMbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7BPFRKSzVyPUeuOFQ6ODhizszN	MVvTRW5ITVJ?
D-263MG	M4TmSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHETWM2OD15LkS1O\|YzKM7:TR?=	NWXyU2ZYW0GQR1XS
NCI-H1355	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XnU2lEPTB;Nz63O\|AzQSEQvF2=	NITIcYxUSU6JRWK=
DSH1	NF\VdYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTdwN{m3OlIh\|ryP	M37QPHNCVkeHUh?=
NCI-H460	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvvVm9KSzVyPUiuNFA3QTRizszN	MmrMV2FPT0WU
NCI-H1563	M2S2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfwSnU2UUN3ME24MlA4PTB6IN88US=>	MUDTRW5ITVJ?
SW948	NGPhdHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrW[XJpUUN3ME24MlExPzR2IN88US=>	NEmxcYdUSU6JRWK=
LK-2	M4HLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfxTWM2OD16LkGyPFM{KM7:TR?=	NEnQ[2lUSU6JRWK=
HT-1080	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRThwMUOxO\|Uh\|ryP	M3rUO3NCVkeHUh?=
NCI-H441	M{iyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWG2WVdRUUN3ME24MlE6OyEQvF2=	M2nxW3NCVkeHUh?=
HSC-4	NUDlUVQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLvTWM2OD16LkK4O\|Ih\|ryP	MkXQV2FPT0WU
LXF-289	MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRThwM{W5OFMh\|ryP	M3LNWnNCVkeHUh?=
MRK-nu-1	M3j0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXnfmxKSzVyPUiuN\|Y{ODRizszN	MV7TRW5ITVJ?
no-11	NXTvO5p[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHLPJhKSzVyPUiuOFcyOzNizszN	Mlq2V2FPT0WU
SNU-387	M2DxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fyOWlEPTB;OD62N\|I1PiEQvF2=	M2HEfXNCVkeHUh?=
Detroit562	NHqyeVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULUW493UUN3ME24Mlc2PDV3IN88US=>	MYTTRW5ITVJ?
SW954	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH[xRZVKSzVyPUiuO\|Y5OzJizszN	Moi2V2FPT0WU
P12-ICHIKAWA	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYD0SHhIUUN3ME24Mlc5QTRizszN	M3fPS3NCVkeHUh?=
TE-9	M4eze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TaS2lEPTB;OD64NVA3OiEQvF2=	MVnTRW5ITVJ?
NB13	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRThwOEO3PVYh\|ryP	M1r0d3NCVkeHUh?=
BPH-1	NIfJfIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLJOYJKSzVyPUiuPFUxQDFizszN	MnW1V2FPT0WU
KMOE-2	NXT6N2l4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLzTWM2OD16Lki3PFkzKM7:TR?=	MkDLV2FPT0WU
RPMI-8402	NW\vR2dDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE[5THRKSzVyPUiuPFk6OjZizszN	MljBV2FPT0WU
OVCAR-3	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PhVmlEPTB;OD65O\|c{OiEQvF2=	NFnQ[pVUSU6JRWK=
NCI-H2196	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrTZnZKSzVyPUiuPVg3ODZizszN	NWLNPFlOW0GQR1XS
MZ7-mel	NYL1RZpNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHlTWM2OD17LkCzOFYh\|ryP	MWrTRW5ITVJ?
GP5d	M1jLcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;jTWM2OD17LkC2N\|E{KM7:TR?=	MlexV2FPT0WU
NCI-N87	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTlwNES3N\|Eh\|ryP	MUDTRW5ITVJ?
EW-16	NFjKdpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrWS4VKSzVyPUmuOFQ5PDhizszN	MkjLV2FPT0WU
Calu-6	NUSyWFJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PQcWlEPTB;OT60PVcxOyEQvF2=	M2\yd3NCVkeHUh?=
LC4-1	Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTlwNkK1O{DPxE1?	NYK4SW1lW0GQR1XS
CCRF-CEM	M3fQfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPFVYNKSzVyPUmuOlg4PjZizszN	MoLEV2FPT0WU
BC-1	M4HNcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXT3VmZkUUN3ME25Mlc5QTlizszN	MWrTRW5ITVJ?
NCI-SNU-16	NH;KNHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DrbGlEPTB;OT63PVQ6PSEQvF2=	Mm\iV2FPT0WU
NCI-H28	NGqzeIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTlwOES5N\|Mh\|ryP	M1f4eHNCVkeHUh?=
SBC-1	MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\IbYxKSzVyPUGwMlA4OiEQvF2=	NX:wb3JNW0GQR1XS
TUR	MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mme3TWM2OD1zMD6xOlU4KM7:TR?=	MVLTRW5ITVJ?
MDA-MB-231	NYXyWmkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrQTWM2OD1zMD6yNVE1KM7:TR?=	Mkm5V2FPT0WU
C3A	NULnS25lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoOxTWM2OD1zMD6zNVc6KM7:TR?=	NF3Xb4JUSU6JRWK=
SW1990	NVPN[4lNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;MWVVbUUN3ME2xNE4{OjhizszN	M4jGdnNCVkeHUh?=
NCI-H1993	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTFyLkW2PVMh\|ryP	MV7TRW5ITVJ?
SK-CO-1	NGDDdpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUCzbnhHUUN3ME2xNE44PzdizszN	M1nRfnNCVkeHUh?=
OAW-28	M3;abWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTFyLkm4PFgh\|ryP	NEn6UZNUSU6JRWK=
HN	NEXLbnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFKxZpVKSzVyPUGxMlEyOzFizszN	NGi3OWNUSU6JRWK=
NCI-H1304	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXyWGNpUUN3ME2xNU4yPTd4IN88US=>	NHWybW1USU6JRWK=
Daoy	NHX6RZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTFzLkSzN\|Yh\|ryP	M4KyNnNCVkeHUh?=
VA-ES-BJ	NHTWVHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTFzLkexPVUh\|ryP	Mo[xV2FPT0WU
MCF7	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHf6dnNKSzVyPUGxMlgyOjZizszN	NXS2XlB[W0GQR1XS
VM-CUB-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvxb4g1UUN3ME2xNU46ODlzIN88US=>	NYThXoc4W0GQR1XS
IPC-298	NV;UW41jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTFzLkmzPFMh\|ryP	NYPDTplIW0GQR1XS
NCI-H2126	M1e3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoP1TWM2OD1zMj6wNlE5KM7:TR?=	M4DxT3NCVkeHUh?=
OVCAR-8	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrVOJFxUUN3ME2xNk4yOTRzIN88US=>	M2r6fHNCVkeHUh?=
SJRH30	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3JW5NjUUN3ME2xNk4zOjl7IN88US=>	MWjTRW5ITVJ?
DMS-53	NV36Wm1oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\lT2lEPTB;MUKuNlY1QSEQvF2=	NFHxfGdUSU6JRWK=
NCI-H322M	NYrwTVNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfWTWM2OD1zMj6zN\|U4KM7:TR?=	NV7wZXBkW0GQR1XS
RVH-421	MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPKTWM2OD1zMj60PVA1KM7:TR?=	Mkm2V2FPT0WU
Raji	NI[ydnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkD1TWM2OD1zMj62NVQh\|ryP	MoraV2FPT0WU
MDA-MB-415	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlq5TWM2OD1zMj62OFQ1KM7:TR?=	MWnTRW5ITVJ?
EFE-184	NF7QdHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTF{LkexNFYh\|ryP	NIXPS2FUSU6JRWK=
BFTC-909	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnT3TWM2OD1zMj65NlQ4KM7:TR?=	MVnTRW5ITVJ?
BHY	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrocZJKSzVyPUGzMlM{QSEQvF2=	NIP5RopUSU6JRWK=
YKG-1	Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH[0e4RKSzVyPUGzMlM4PDlizszN	MkDCV2FPT0WU
EW-3	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfUU\|RnUUN3ME2xN{44OTZ\|IN88US=>	MmXjV2FPT0WU
HCC1143	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTF\|Lke0N\|ch\|ryP	NEPKWVlUSU6JRWK=
REH	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\0VWlEPTB;MUOuPFk5OiEQvF2=	NIDaUZBUSU6JRWK=
CESS	NV\pU3FET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLaTWM2OD1zMz65OFg6KM7:TR?=	MlzzV2FPT0WU
EFM-19	M4XK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\pN2lEPTB;MUSuNVEyOiEQvF2=	MV;TRW5ITVJ?
U031	NE\jeWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzReJBnUUN3ME2xOE41ODh3IN88US=>	NYDzO24zW0GQR1XS
ES1	NILoSnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEP4Nm9KSzVyPUG0MlQ5PTFizszN	MYfTRW5ITVJ?
HSC-3	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnHb3lwUUN3ME2xOE43OjF3IN88US=>	Ml\tV2FPT0WU
LOXIMVI	MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIH6fWFKSzVyPUG0MlcxPjhizszN	NFvYOI1USU6JRWK=
A388	NH6wOoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnpSHQ5UUN3ME2xOE44PTV4IN88US=>	Mn74V2FPT0WU
KP-N-YS	MnLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLITGVqUUN3ME2xOE44PzNizszN	NYW0UXA6W0GQR1XS
Capan-2	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;j[FZKSzVyPUG0Mlc5PiEQvF2=	NH:yNGxUSU6JRWK=
SKG-IIIa	M3u3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rzTWlEPTB;MUSuPFg3OiEQvF2=	NVT5eVRnW0GQR1XS
HEL	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjaWWtKSzVyPUG0Mlg6QTdizszN	NWPFOXgxW0GQR1XS
BEN	M3;k[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjxd4hKSzVyPUG0Mlk4PjZizszN	MmHIV2FPT0WU
MC116	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rTXmlEPTB;MUWuNVU6QSEQvF2=	M1jySHNCVkeHUh?=
IGROV-1	MknTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHryPG9KSzVyPUG1MlI{OTdizszN	NIfCV5JUSU6JRWK=
NCI-H1648	NGKzelhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fvWmlEPTB;MUWuOVMxPSEQvF2=	Mni3V2FPT0WU
ABC-1	M1Oyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\zcGlEPTB;MUWuPFA{OyEQvF2=	Mlq2V2FPT0WU
EW-18	M2H2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3Kc\|dZUUN3ME2xOU46QTd7IN88US=>	MnKyV2FPT0WU
BC-3	M{XCNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLlZ\|BKSzVyPUG2MlA2PjJizszN	MlLIV2FPT0WU
NCI-H1437	NVKxVWU5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fOeGlEPTB;MU[uNFY3PyEQvF2=	NX\m[4dkW0GQR1XS
SCC-15	NFKwWY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrFeJZKSzVyPUG2MlI5OjVizszN	NHnzV4FUSU6JRWK=
TT	NFPkTZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGS4eYZKSzVyPUG2MlU5QDhizszN	NVvkNmJPW0GQR1XS
KINGS-1	M3u3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzKO\|RKSzVyPUG2MlgzPzNizszN	MnrLV2FPT0WU
C32	M{TiV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\YbmNKSzVyPUG2Mlk4OTdizszN	M37jdXNCVkeHUh?=
SBC-5	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXGSVdKSzVyPUG3MlE1PzlizszN	NF\3ZXFUSU6JRWK=
NB1	NEf0NppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLSSGZ5UUN3ME2xO{4{OTh6IN88US=>	MmqwV2FPT0WU
EB-3	NHvldHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvVOI9jUUN3ME2xO{42PzZizszN	NWjnXIs{W0GQR1XS
NCI-H748	NGj2SIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTF5LkewN\|Uh\|ryP	NXjJSnh4W0GQR1XS
IST-SL1	M2rLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUf4e3NmUUN3ME2xO{44PTJ4IN88US=>	Ml7TV2FPT0WU
WM-115	MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjhbJRlUUN3ME2xO{45ODh3IN88US=>	NECxPVlUSU6JRWK=
NCI-H226	M1fK[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3Q[HVKSzVyPUG3Mlk2PDZizszN	NX3URWhIW0GQR1XS
CAL-33	NIHQUXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jLV2lEPTB;MUiuNlc5OSEQvF2=	MXPTRW5ITVJ?
SCC-4	NWnoV3N1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnZTWM2OD1zOD6zNlI6KM7:TR?=	MXPTRW5ITVJ?
RMG-I	M4LkcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFS0UIRKSzVyPUG4MlY6PDdizszN	NVL1[JByW0GQR1XS
KOSC-2	NWXuZXhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXzTol2UUN3ME2xPE44PzR4IN88US=>	M2HIW3NCVkeHUh?=
A2058	NVT2cnBXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HJN2lEPTB;MUiuPFI2PSEQvF2=	NXLtNIZbW0GQR1XS
HCC70	NFWyVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTF7LkO4PVQh\|ryP	M1jFcHNCVkeHUh?=
C2BBe1	M4PwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LhbmlEPTB;MUmuOFE1QCEQvF2=	NHXJOYdUSU6JRWK=
NCI-H650	Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPKTWM2OD1zOT61PFk6KM7:TR?=	M4n4bnNCVkeHUh?=
CAL-72	NES5UYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTEWpRDUUN3ME2xPU43PzN5IN88US=>	M{HPdHNCVkeHUh?=
L-363	NXmzRlZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIj3UmZKSzVyPUKwMlAzOTJizszN	NHPCeFJUSU6JRWK=
SNU-423	MlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXyTWM2OD1{MD6xNFQ{KM7:TR?=	MUfTRW5ITVJ?
PLC-PRF-5	M1zOeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTJyLkO5NFYh\|ryP	MYTTRW5ITVJ?
SW1463	NIG4[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTJyLkS1NlUh\|ryP	M1nxZ3NCVkeHUh?=
769-P	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nlPWlEPTB;MkCuOlc3QSEQvF2=	M4PxdXNCVkeHUh?=
DMS-79	NEXIU4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\yPJREUUN3ME2yNE45PDlizszN	MUPTRW5ITVJ?
Saos-2	MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTJyLkm1OVYh\|ryP	NF;XbodUSU6JRWK=
CHP-126	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUSzZ3FGUUN3ME2yNU41PDZ{IN88US=>	NEDTWWVUSU6JRWK=
SW837	Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rRTmlEPTB;MkGuOFk{QSEQvF2=	Ml\1V2FPT0WU
SHP-77	MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDRZopKSzVyPUKxMlYyOjJizszN	MXjTRW5ITVJ?
DB	NEm0[XhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYmxS5NoUUN3ME2yNU43OTR{IN88US=>	M4PZ[XNCVkeHUh?=
ES5	NVzK[2RJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;RT2lEPTB;MkGuOlg3PCEQvF2=	NG\OZlZUSU6JRWK=
COR-L23	NGO0U2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPaNZoyUUN3ME2yNU45ODVzIN88US=>	MYrTRW5ITVJ?
KU-19-19	MkLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjwRXlKSzVyPUKxMlg6QDJizszN	MVPTRW5ITVJ?
T84	M4PEfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzFTWM2OD1{MT65PFE6KM7:TR?=	NITNS2hUSU6JRWK=
NCI-H630	Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjDSGNxUUN3ME2yNk42OzZ\|IN88US=>	M{PicHNCVkeHUh?=
LU-165	NUDvVGs4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDRVJNKSzVyPUKyMlU2PCEQvF2=	MYPTRW5ITVJ?
COLO-792	NFrlbXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PFbGlEPTB;MkKuO\|EyOSEQvF2=	NG[wZoJUSU6JRWK=
CAL-62	NUPiNFNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rMTWlEPTB;MkKuO\|UyPyEQvF2=	Mmr1V2FPT0WU
HCE-T	MnW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3iwZ2lEPTB;MkKuPFYxPiEQvF2=	MljDV2FPT0WU
BB65-RCC	NEXxR\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1f2fGlEPTB;MkOuNFM1PCEQvF2=	MVLTRW5ITVJ?
SiHa	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTJ\|LkO5Olgh\|ryP	M1OwcHNCVkeHUh?=
NCI-H2081	NI\ncZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XhNGlEPTB;MkSuNFY1OSEQvF2=	M3L4UXNCVkeHUh?=
U251	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTJ2LkC2Olgh\|ryP	MV7TRW5ITVJ?
LoVo	NWPvSYRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfITWM2OD1{ND65NlgzKM7:TR?=	NYfVc5hlW0GQR1XS
GCIY	MlLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7qVoJoUUN3ME2yOU4zQDd5IN88US=>	M2LvR3NCVkeHUh?=
NUGC-3	NWDGRm5RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfkdZlKSzVyPUK1MlM{OTZizszN	M1PwbnNCVkeHUh?=
LNCaP-Clone-FGC	NYThb4VjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTJ3LkO0PVgh\|ryP	MV3TRW5ITVJ?
PA-1	M2mzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXDXmZwUUN3ME2yOU43QDN\|IN88US=>	NIjkZZdUSU6JRWK=
OE33	M1LiNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LSdWlEPTB;MkWuOlg2OyEQvF2=	M3r2SnNCVkeHUh?=
HT-29	Mk[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUSxS\|NZUUN3ME2yOU44QDd7IN88US=>	NU\HbmVpW0GQR1XS
RCM-1	M1fYemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGi2b4pKSzVyPUK1Mlk3PTZizszN	MmqxV2FPT0WU
NCI-H1522	MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHkTWM2OD1{NT65PVEyKM7:TR?=	NFPpZ49USU6JRWK=
LB373-MEL-D	NV60[XM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2C1S2lEPTB;Mk[uNVcxQCEQvF2=	M2jSPHNCVkeHUh?=
NCI-H1436	M1fLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3tOGdzUUN3ME2yOk4zPzN6IN88US=>	MnXwV2FPT0WU
COLO-824	NVzxOXBWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTJ4LkSwNFIh\|ryP	MUPTRW5ITVJ?
CP50-MEL-B	NIfMZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3r5[mlEPTB;Mk[uOVY4PSEQvF2=	M2LTfHNCVkeHUh?=
EGI-1	M2G4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTJ5LkK2PVgh\|ryP	NI[4bo5USU6JRWK=
LAN-6	NFvGUXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTJ5LkO1PVgh\|ryP	NH6xSZZUSU6JRWK=
GAK	M16xW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfTVIFKSzVyPUK3MlQzOjVizszN	MW\TRW5ITVJ?
MDA-MB-175-VII	NHjUV2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTJ5LkWwOVMh\|ryP	MmXGV2FPT0WU
JVM-2	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTJ5Lk[2NlIh\|ryP	MWfTRW5ITVJ?
UACC-257	MmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTTeol1UUN3ME2yO{43QDd6IN88US=>	MoPyV2FPT0WU
SW1783	NEjpRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXHTWM2OD1{Nz63O\|g{KM7:TR?=	NHvOc5NUSU6JRWK=
HT-3	Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mof2TWM2OD1{OD6yNVY3KM7:TR?=	NVfrWZhMW0GQR1XS
RL	M2DaTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHWWJhKSzVyPUK4MlU6OTFizszN	MorPV2FPT0WU
TK10	Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;4fnc2UUN3ME2yPE43PTN3IN88US=>	M1X5bHNCVkeHUh?=
HT55	MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4ew[2lEPTB;MkmuNFU3PSEQvF2=	MnfQV2FPT0WU
BT-20	NELiT2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETvbJpKSzVyPUK5MlA2QDZizszN	NXf5WIozW0GQR1XS
TGBC24TKB	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXQWVFqUUN3ME2yPU4yQDNzIN88US=>	NHXufGJUSU6JRWK=
HSC-2	MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmToTWM2OD1{OT6zNFAyKM7:TR?=	MlvYV2FPT0WU
COLO-205	NXLyO2pyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3mZ4pKSzVyPUK5MlM6PDRizszN	MW\TRW5ITVJ?
GT3TKB	M4\qVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTJ7Lk[4O\|ch\|ryP	M33s[HNCVkeHUh?=
T47D	NVr1WW9zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDXTWM2OD1{OT64OVgzKM7:TR?=	MnLCV2FPT0WU
OMC-1	M4DETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnjb\|FKSzVyPUOwMlE6OTlizszN	NWLmWIhxW0GQR1XS
PFSK-1	NVHteG96T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13ubmlEPTB;M{GuNlY2QSEQvF2=	M3PQWXNCVkeHUh?=
JEG-3	M{jMfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmH1TWM2OD1\|MT6zOVYyKM7:TR?=	M3HRTHNCVkeHUh?=
RD	MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1z1T2lEPTB;M{GuOVEyPSEQvF2=	NHnFdohUSU6JRWK=
NCI-H64	Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7COG9XUUN3ME2zNk41OTd7IN88US=>	NGHDfZNUSU6JRWK=
DMS-114	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXiTWM2OD1\|Mj60NVgzKM7:TR?=	MoTIV2FPT0WU
NCI-H661	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTN{Lk[1NFEh\|ryP	MmjRV2FPT0WU
CAL-148	NHLB[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjOTWM2OD1\|Mj62OlY2KM7:TR?=	MVrTRW5ITVJ?
HuP-T3	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTpb4xtUUN3ME2zNk46OzN6IN88US=>	NULkWIhJW0GQR1XS
ES4	NYjZXodJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEH1ZoVKSzVyPUOzMlE4ODVizszN	NIr3VnBUSU6JRWK=
Ca9-22	NYO2OJpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPITWM2OD1\|Mz60OlAyKM7:TR?=	NGTHPGhUSU6JRWK=
LP-1	M3T2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX74TnlLUUN3ME2zOE4xQSEQvF2=	MnS1V2FPT0WU
AU565	MnHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTN2LkWwOlkh\|ryP	M4q5dXNCVkeHUh?=
MDA-MB-453	Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HvPWlEPTB;M{WuNVQzPiEQvF2=	MWLTRW5ITVJ?
SNU-C1	MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEWze4JKSzVyPUO1MlE4OSEQvF2=	NWCwU4FCW0GQR1XS
SW13	NGTYU4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnnN4pbUUN3ME2zOU41ODd4IN88US=>	NUTWOIJ5W0GQR1XS
NCI-H2122	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHvdIhKSzVyPUO1MlU2QThizszN	NXjDTIVFW0GQR1XS
NCI-H1395	NIfZNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELRSJBKSzVyPUO1MlY3QTFizszN	MkXSV2FPT0WU
J-RT3-T3-5	NFnxTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTN4LkCyPVQh\|ryP	MVzTRW5ITVJ?
COR-L279	MkTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3CTWM2OD1\|Nj6xPVgyKM7:TR?=	MWrTRW5ITVJ?
ATN-1	M1HmXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGSxXpBKSzVyPUO2Mlg2OTZizszN	MXLTRW5ITVJ?
HCC2998	NIDsU2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTtTIhZUUN3ME2zOk45PTdzIN88US=>	MnfkV2FPT0WU
UM-UC-3	NVfjS3U3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFmyW5FKSzVyPUO2Mlg3PzVizszN	NHjGWmNUSU6JRWK=
DV-90	NIjqNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjnOIVKSzVyPUO2MlkxPjdizszN	M1TvXHNCVkeHUh?=
ES8	NVvOU\|VnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTN4LkmzNVgh\|ryP	MlXtV2FPT0WU
YAPC	NHjEelJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTN4Lkm2OVQh\|ryP	MXnTRW5ITVJ?
HCC1599	NE\jXGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjWcVZKSzVyPUO3MlE3OThizszN	NYDPSpFYW0GQR1XS
UMC-11	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTN5LkK1NFMh\|ryP	M3vh[3NCVkeHUh?=
THP-1	M4DaSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHVTWM2OD1\|Nz6yPFY5KM7:TR?=	NFyyOGRUSU6JRWK=
OCUB-M	M2q1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HtSWlEPTB;M{euNlg6OSEQvF2=	NVj6S3pLW0GQR1XS
NCI-H1693	NVz3W5ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjSW49rUUN3ME2zO{4{OjN\|IN88US=>	MlHzV2FPT0WU
NCI-H345	MkLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfoTWM2OD1\|Nz6zOlI1KM7:TR?=	MV7TRW5ITVJ?
COLO-800	NFvSeIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHsempKSzVyPUO3MlU3PyEQvF2=	NFnNcJVUSU6JRWK=
COLO-320-HSR	NW\XSFhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHnepk3UUN3ME2zPE4{PDl{IN88US=>	NETEPWhUSU6JRWK=
NCI-H596	M{fkT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrrfGRKSzVyPUO4MlQ1QDlizszN	MlzYV2FPT0WU
NCI-H187	M37ofGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7kdFhSUUN3ME2zPE44OzR2IN88US=>	M325O3NCVkeHUh?=
ECC4	NX3melZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4THcGlEPTB;M{muNFgyPCEQvF2=	MVfTRW5ITVJ?
KP-4	NGKxSIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTN7LkGyN\|Uh\|ryP	M{nifXNCVkeHUh?=
NCI-H2227	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7LbGJUUUN3ME2zPU4{QTR7IN88US=>	M3ixZ3NCVkeHUh?=
22RV1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELidnVKSzVyPUO5Mlg{QThizszN	NHrhUXVUSU6JRWK=
SAS	MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HhcWlEPTB;NECuNFk3KM7:TR?=	NGDWS45USU6JRWK=
PANC-10-05	M1fBZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M175U2lEPTB;NECuNVgzQCEQvF2=	NHv4Z\|BUSU6JRWK=
MDA-MB-468	NFPENWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlS4TWM2OD12MD61N\|Q3KM7:TR?=	M4fwW3NCVkeHUh?=
RPMI-7951	NXHwemlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4K1dmlEPTB;NEGuNlA4PSEQvF2=	NVXrdZhOW0GQR1XS
BB49-HNC	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHPe4s6UUN3ME20NU4zOTd7IN88US=>	MlK1V2FPT0WU
23132-87	NV\IV44yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\4fZZjUUN3ME20NU4zPzN{IN88US=>	M{HmbHNCVkeHUh?=
HCC1569	NG[4dodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTRzLkK4PFUh\|ryP	M1XhPXNCVkeHUh?=
CP66-MEL	M{XBUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDNTYNrUUN3ME20Nk4yQDh4IN88US=>	Mlv1V2FPT0WU
K-562	Mo\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\ycnE3UUN3ME20Nk4zQDV2IN88US=>	MYPTRW5ITVJ?
OCI-AML2	M1zxdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTR{Lki5O\|Qh\|ryP	NU\rdo5ZW0GQR1XS
SW756	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnOTWM2OD12Mz6wN\|g5KM7:TR?=	MWjTRW5ITVJ?
M14	NY\EXpYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1f1eGlEPTB;NEOuN\|E5QSEQvF2=	NUK2TGlDW0GQR1XS
NCI-H1623	NYOxVGZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jCfWlEPTB;NEOuOFY1KM7:TR?=	NXn1bplpW0GQR1XS
KNS-81-FD	MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTR\|Lke2NkDPxE1?	MXPTRW5ITVJ?
TGBC1TKB	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTR\|LkmwPVkh\|ryP	NHLKOXdUSU6JRWK=
RERF-LC-MS	NX3RRmNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLudWNTUUN3ME20N{46OjhzIN88US=>	NX36N3JFW0GQR1XS
PC-3	NYjrSW5iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX:yTVNrUUN3ME20OE41OzR5IN88US=>	MX;TRW5ITVJ?
HuP-T4	NVHqS3lUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnJR2Q3UUN3ME20OE41PDd2IN88US=>	MXTTRW5ITVJ?
NCI-H510A	NYG4UHdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHGTWM2OD12ND63NFgh\|ryP	MYHTRW5ITVJ?
LB2518-MEL	M1;6cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGn1NppKSzVyPUS0Mlc6OzdizszN	Mn7pV2FPT0WU
TE-5	M3jicGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorqTWM2OD12NT65OVgyKM7:TR?=	NF:1PYRUSU6JRWK=
EW-24	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvmTWM2OD12Nj6xO\|I{KM7:TR?=	Mn7KV2FPT0WU
LB647-SCLC	NXTJOmY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zlbGlEPTB;NE[uNlE2PSEQvF2=	MkT0V2FPT0WU
NCI-H524	M3nWOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTR4LkexPFUh\|ryP	M{Tsb3NCVkeHUh?=
EW-11	M1\MeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWW0NYY3UUN3ME20Ok46Ozd\|IN88US=>	NVTMTYtqW0GQR1XS
KALS-1	NXXNXnFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTR5LkKwOlYh\|ryP	MXPTRW5ITVJ?
BT-474	MnvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjr[nhyUUN3ME20O{41OjF4IN88US=>	MX7TRW5ITVJ?
SK-N-AS	NEP5e5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIO0Zm9KSzVyPUS3Mlg5QCEQvF2=	NVL5WmJLW0GQR1XS
HCC2157	M1LNcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvZSXNWUUN3ME20PE4xPzZizszN	M2HUcnNCVkeHUh?=
HCC1954	M2jjd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXuxfW9OUUN3ME20PE4yPzB2IN88US=>	NXrwVlVjW0GQR1XS
FADU	MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXmTWM2OD12OD6zNFMyKM7:TR?=	MkHlV2FPT0WU
S-117	NETpVHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTR6LkO4NVUh\|ryP	NWLPcIptW0GQR1XS
LS-1034	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTR6LkewOlch\|ryP	MmPpV2FPT0WU
CAMA-1	Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYC3UndVUUN3ME20PU42PTR\|IN88US=>	MmixV2FPT0WU
LU-134-A	Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnJRVlKSzVyPUS5MlgxQDVizszN	MUTTRW5ITVJ?
NCI-H1838	MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4T2b2lEPTB;NEmuPFA5PyEQvF2=	MlLIV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pSrc / Src / pPlcg / Plcg / pStat5 / Stat5 ; PubMed: 22781593 Leukemia In (B) inhibition of Src, Plcg and Stat5 was seen in MLNAF cell lines treated with Ponatinib; ZNF112 expresses ZMYM2–FGFR1, CEP2A and CEP5A cells express CEP110–FGFR1 and BBC2 expresses BCR–FGFR1. pFGFR1(pY20) / FGFR1; PubMed: 22781593 Leukemia Western blot analysis, using various antibodies specific for downstream targets of FGFR1, demonstrates that Ponatinib inhibits the activation of Plcg and Src as a result of inhibiting the FGFR1 fusion kinase in human KG1 cells. cleaved caspase-3 / cleaved caspase-7 / BAX / Bcl-2; PubMed: 30959969 Molecules Western blot analysis of cleaved caspase-3, cleaved caspase-7, Bax, Bcl-2, and β-Tubulin (control) in treated cells. p-Rb(S807/811) / Rb / CDK4 / CDK6 / Cyclin D1 / CDK2 / Cyclin E1; PubMed: 30959969 Molecules Western blot analysis of Rb/p-Rb, CDK4, CDK6, Cyclin D1, CDK2, Cyclin E1, and β-Tubulin (control) in the SK-Hep-1 and SNU-423 cells treated with ponatinib. RAD51; PubMed: 30959969 Molecules The effect of ponatinib on the concentration of Rad51 in SK-Hep-1 and SNU-423 cells. p-MEK / MEK / p-ERK / ERK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Mek and Erk. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. c-Jun / p-JNK(T183/Y185) / JNK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of JNK and c-Jun. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-p38 MAPK / p38 MAPK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of p38. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-JAK2 / JAK2 / p-STAT3 / STAT3; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Jak2, and Stat3. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. PI3K p85 / p-PI3K / p-PDK1 / PDK1 / p-mTOR / mTOR; PubMed: 30959969 Molecules Effects of ponatinib on the protein concentration and phosphorylation of PI 3-kinase, PDK1, Akt, and mTOR in HCC cells. p-PDGFRα / PDGFRα; PubMed: 24472312 Mol Cancer Ponatinib inhibited phosphorylation of PDGFRα in a concentration-dependent manner. EOL-1 and BaF3-WT or -T674I FIP1L1-PDGFRα cells were exposed to escalating concentrations of ponatinib for 24 h. PARP / Caspase-3 / Active Caspase-3; PubMed: 24472312 Mol Cancer The concentration- (for 24 h) and time-dependent (1 nM for EOL-1, 300 nM for BaF3-WT and -T674I FIP1L1-PDGFRα cells) cleavage of PARP and caspase-3 triggered by ponatinib was analyzed by immunoblotting. AIF / Cyto C ; PubMed: 24472312 Mol Cancer Ponatinib elicited release of AIF and cytochrome c into the cytosol. Cells were treated with 1 nM ponatinib for the indicated durations and the cytosolic fraction was extracted with digitonin buffer. Levels of AIF and Cytochrome c (Cyto c) were detected by immunoblotting. Mcl-1 / Survivin / Bcl-Xl / XIAP / Bax / Bcl-2 / Bim; PubMed: 24472312 Mol Cancer Immunoblotting of apoptosis-related proteins in CEL cells after treatment for 24 h. β-catenin ; PubMed: 24472312 Mol Cancer Ponatinib concentration-dependently lowered β-catenin. EOL-1 cells were incubated with ponatinib for 24 h, and cytoplasmic and nuclear extracts were determined by immunoblotting. β-catenin; PubMed: 24472312 Mol Cancer Analysis of β-catenin localization. EOL-1 cells were pretreated with 1 nM ponatinib for 24 h, immunofluorescence analysis was performed with anti-β-catenin. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). ABL; PubMed: 19878872 Cancer Cell In vitro [γ-32P]-ATP autophosphorylation of full-length (A) ABL or (B) ABLT315I kinase treated with AP24534, imatinib, nilotinib, or dasatinib. After incubation of tyrosine-dephosphorylated enzyme with the indicated inhibitor in the presence of [γ-32P]-ATP and separation by SDS-PAGE, signal intensity was measured by autoradiography.	22781593 30959969 24472312 19878872
Growth inhibition assay	Cell viability; PubMed: 30174789 Oncotarget (A) Effect of Ponatinib on basal viability of HUVECs. The cells were treated with Ponatinib at indicated concentrations or 0.1% DMSO (vehicle control) for 24 h.	30174789

In vivo

In a mouse xenograft model of Ba/F3 cells expressing native Bcr-Abl, AP24534 (2.5 mg/kg and 5 mg/kg) prolongs mice median survival. In the xenograft model of Ba/F3 Bcr-Abl^T315I, AP24534 (10 mg/kg–50 mg/kg) significantly suppresses tumor growth. AP24534 (30 mg/kg) decreases the phosphorylated Bcr-Abl and phosphorylated CrkL levels in the tumors. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Peptide substrate phosphorylation assays with GST-Abl kinase domains: The effect of AP24534 (0-320 nM) on GST-Abl kinase activity is assessed by using a synthetic peptide substrate (Abltide: EAIYAAPFAKKK). Assays are carried out at 30 °C for 15 min in 25 μL reaction mixture: 8 mM MOPS (pH 7), 0.2 mM EDTA, 50 μM Abltide, 30 mM MgCl₂, 10 mM β-glycerol phosphate, 1 mM EGTA, 0.002% Brij-35, 0.4 mM DTT, 0.2 mg/mL BSA, 0.4 mM sodium orthovanadate, 10 nM WT or mutant GST-Abl kinase, and 100 µM ATP/γ-³²[P]ATP (5000 cpm/pmol). Reactions are terminated by transferring a portion of the reaction mixture onto a p81 phosphocellulose filter and immersing in 0.75% phosphoric acid. Filters are washed 3 times in 0.75% phosphoric acid, rinsed in acetone, and air dried; phosphate incorporation is determined by scintillation counting. All results are corrected for background binding to the filters, as determined by omitting peptide substrate from the kinase reaction. Time course experiments to establish the linear range of enzymatic activity precedes kinase assays.
Cell Research:^[2]	- Collapse Cell lines: Ba/F3 cells expressing Bcr-Abl or a range of single mutations in the kinase domain of Bcr-Abl Concentrations: 0-625 nM Incubation Time: 72 hours Method: Ba/F3 cell lines are distributed in 96-well plates (4 × 10³ cells/well) and incubated with AP24534 for 72 hours. Proliferation is measured using a methanethiosulfonate (MTS)-based viability assay (CellTiter96 Aqueous One Solution). All values are normalized to the control wells with no drug. IC50 values are reported as the mean of three independent experiments performed in quadruplicat (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Mouse xenograft models of Ba/F3 cells expressing Bcr-Abl or Bcr-Abl^T315I Formulation: Dissolved in 25 mM citrate buffer, pH 2.75 Dosages: 2.5 mg/kg and 5 mg/kg for Ba/F3 Bcr-Abl; 2.5 mg/kg–50 mg/kg for Ba/F3 Bcr-Abl^T315I Administration: Oral gavage once daily (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	30 mg/mL (56.33 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% CMC Na For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Ponatinib (AP24534) SDF

Molecular Weight	532.56
Formula	C₂₉H₂₇F₃N₆O
CAS No.	943319-70-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04070443	Not yet recruiting	Drug: Ponatinib\|Drug: Imatinib	Philadelphia Chromosome Positive CML\|BCR-ABL Positive Chronic Myelogenous Leukemia	Centre Leon Berard	October 1 2019	Phase 2
NCT03934372	Not yet recruiting	Drug: Ponatinib	Acute Myeloid Leukemia\|Accelerated Phase Chronic Myeloid Leukemia\|Blast Phase Chronic Myeloid Leukemia\|Chronic Phase Chronic Myeloid Leukemia\|Acute Lymphoblastic Leukemia\|Acute Lymphocytic Leukemia\|Leukemia\|Lymphoma\|Solid Tumors	Incyte Biosciences International Sàrl\|Incyte Corporation	October 25 2019	Phase 1\|Phase 2
NCT03895671	Recruiting	Drug: Ponatinib\|Drug: Azacitidine	CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE\|CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS	Versailles Hospital	June 19 2019	Phase 2
NCT03690115	Recruiting	Drug: Ponatinib 30 MG	Leukemia Myeloid Acute	Versailles Hospital	December 12 2018	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is the pre-solubilized inhibitor suitable for in vivo whole animal studies? Whether the solvent contains any non-DMSO stabilizer?
Answer:
Our 10mM Ponatinib in DMSO solution is in pure DMSO and there is not other stabilizer added. You can use it for animal study. The vehicle we suggest for Ponatinib is: 30% PEG400/0.5% Tween80/5% Propylene glycol. It is a milky suspension used for oral gavage.

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

Selective Bcr-Abl Inhibitor

Nilotinib (AMN-107) : Bcr-Abl-selective, IC50<30 nM.
Most Potent Bcr-Abl Inhibitor

GZD824 : Bcr-Abl(WT), IC50=0.34 nM; Bcr-Abl(T315I), IC50=0.68 nM.
FDA-approved Bcr-Abl Inhibitor

Dasatinib : Approved by FDA for CML and Ph+ ALL.
Newest Bcr-Abl Inhibitor

GZD824 : Orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

Related Bcr-Abl Products

PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.
Defactinib (VS-6063, PF-04554878) ^New

Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.
SU6656 ^New

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
Imatinib Mesylate (STI571)

Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.
Nilotinib (AMN-107)

Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.

Features:A selective inhibitor of native and mutant Bcr-Abl.
Bafetinib (INNO-406)

Bafetinib (INNO-406) is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM/19 nM in cell-free assays, does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and c-Kit. Phase 2.

Features:Dual Bcr-Abl/Lyn inhibitor.
Degrasyn (WP1130)

Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT).

Features:WP1130 has an advantage over imatinib mesylate in that its activity is not inhibited by a variety of Abl kinase mutations, including T315I.
Rebastinib (DCC-2036)

Rebastinib (DCC-2036) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1.

Features:A conformational control inhibitor of Abl1 and T315I Abl1.
GZD824 Dimesylate(HQP1351)

GZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.
GNF-2

GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl, shows no activity to Flt3-ITD, Tel-PDGFR, TPR-MET and Tel-JAK1 transformed tumor cells.

Choose Your Country or Region

By Signaling Pathways

By product type

Ponatinib (AP24534)

Cited by 83 Publications

Purity & Quality Control

Choose Selective Bcr-Abl Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Ponatinib (AP24534) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

Related Bcr-Abl Products

Choose Your Country or Region

By Signaling Pathways

By product type

Ponatinib (AP24534)

Cited by 83 Publications

Purity & Quality Control

Choose Selective Bcr-Abl Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Ponatinib (AP24534) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

Related Bcr-Abl Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)